Anticoagulation for Mesenteric Ischemia

Mesenteric Venous Thrombosis (MVT)

The American College of Cardiology recommends starting unfractionated heparin intravenously or therapeutic-dose LMWH subcutaneously immediately upon diagnosis of mesenteric venous thrombosis, achieving >80% recanalization rates and preventing progression to bowel infarction 1, 2
The European Society of Cardiology guidelines suggest that unfractionated heparin was used in 25% of patients and LMWH in 65% in the largest prospective European study 1
The American Heart Association recommends transitioning to oral anticoagulation (warfarin targeting INR 2-3 or direct oral anticoagulants) after 7-10 days of parenteral therapy, and continuing anticoagulation for a minimum of 6 months 1, 2
Portal vein recanalization occurs in 38-39% of patients at 1 year, and mesenteric vein recanalization occurs in 61-73% of patients at 1 year 1, 2
Anticoagulation reduces mortality (HR 0.23), recurrent VTE (HR 0.42), and major bleeding (HR 0.47) compared to no treatment 1, 2

The Society for Vascular Surgery guidelines recommend anticoagulation as adjunctive therapy alongside endovascular or surgical revascularization in acute mesenteric thrombosis 3
The American College of Radiology guidelines suggest that if peritoneal signs, pneumoperitoneum, or intramural air on CT are present, proceed directly to urgent surgery rather than thrombolysis 4, 5

The Society for Vascular Surgery guidelines favor endovascular revascularization as initial treatment based on meta-analysis of 100 observational studies 7
Systemic anticoagulation has no role in chronic mesenteric ischemia before revascularization 7, 6

The American College of Cardiology recommends never delaying anticoagulation while awaiting complete thrombophilia workup or definitive diagnosis if clinical suspicion is high 1, 2
The American Heart Association suggests that immediate anticoagulation is mandatory once nonobstructive MVT is diagnosed 1
The Society for Vascular Surgery guidelines recommend not discontinuing heparin perioperatively if surgery becomes necessary unless active bleeding occurs 1, 2

The American College of Cardiology recommends considering catheter-directed thrombolysis only in MVT patients with high-risk features who fail anticoagulation but have not developed peritonitis 1, 2
A study showed that catheter-directed thrombolysis via the SMA resulted in significantly higher rates of complete thrombus removal (80% vs 29%), lower rates of repeat laparotomy and bowel resection (71% vs 20%), and significantly higher 1-year survival (93% vs 53%) 7